Fig. 2From: Impact of PCSK9 inhibitors in glycaemic control and new-onset diabetesEvolution of fasting glucose, A1c and BMI in DM patients at baseline on PCSK9iFollow-up 3.2 years. Only significant differences were found in BMIA1c: glycated haemoglobin. BMI: body mass index. NS: not significantBack to article page